Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Hu, W.-S. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Hu, W.-S.

 Previous Article  |  Next Article 

Journal of Virology, September 2008, p. 8253-8261, Vol. 82, No. 17
0022-538X/08/$08.00+0     doi:10.1128/JVI.02663-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Capsid Proteins from Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus SIV_mac Can Coassemble into Mature Cores of Infectious Viruses

Jianbo Chen,¹ Vinay K. Pathak,¹ Weiqun Peng,² and Wei-Shau Hu^1*

HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702,¹ Department of Physics, The George Washington University, 725 21st St. NW, Corcoran Hall Room 105, Washington, DC 20052²

Received 14 December 2007/ Accepted 16 June 2008

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
We have recently shown that the Gag polyproteins from human immunodeficiency virus type 1 (HIV-1) and HIV-2 can coassemble and functionally complement each other. During virion maturation, the Gag polyproteins undergo proteolytic cleavage to release mature proteins including capsid (CA), which refolds and forms the outer shell of a cone-shaped mature core. Less than one-half of the CA proteins present within the HIV-1 virion are required to form the mature core. Therefore, it is unclear whether the mature core in virions containing both HIV-1 and HIV-2 Gag consists of CA proteins from a single virus or from both viruses. To determine whether CA proteins from two different viruses can coassemble into mature cores of infectious viruses, we exploited the specificity of the tripartite motif 5 protein from the rhesus monkey (rhTRIM5) for cores containing HIV-1 CA (hCA) but not the simian immunodeficiency virus SIV_mac CA protein (sCA). If hCA and sCA cannot coassemble into the same core when equal amounts of sCA and hCA are coexpressed, the infectivities of such virus preparations in cells should be inhibited less than twofold by rhTRIM5. However, if hCA and sCA can coassemble into the same core structure to form a mixed core, rhTRIM5 would be able to recognize such cores and significantly restrict virus infectivity. We examined the restriction phenotypes of viruses containing both hCA and sCA. Our results indicate that hCA and sCA can coassemble into the same mature core to produce infectious virus. To our knowledge, this is the first demonstration of functional coassembly of heterologous CA protein into the retroviral core.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Coinfection of two distinct retroviruses in the same host occurs in nature. For example, a significant human population is currently coinfected with human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct lentiviruses (2, 19, 25). Phylogenetic analyses of the primate lentiviruses indicate that some of the viruses are recombinants of two distinct parental viruses (3, 37), indicating that the two parental viruses must coinfect the same host and infect the same target cells. Coinfection allows interactions between two viruses by several mechanisms including recombination and pseudotyping. Recombination generates a progeny different from the two parents; the best known example is that simian immunodeficiency virus SIV_cpz, the zoonotic precursor of HIV-1, is thought to be a recombinant of SIV_rcm and SIV_gsn (3). Pseudotyping refers to virions containing components from two different viruses. A commonly observed example of pseudotyping is the use of Env proteins from different viruses, although pseudotyping can occur with many other virion components. Pseudotyped viruses often have properties different from those of virions containing components from one virus; for example, Env-pseudotyped viruses can have a different host range (27, 40).

In all retroviruses, the major structural proteins are encoded by the gag gene, which is translated into the Gag polyprotein. During virus assembly, Gag coordinates the incorporation of other viral proteins and viral RNA and interacts with the host cell machinery to facilitate the release of viral particles (15, 20, 43). In orthoretroviruses, most of the newly released particles are "immature"; virus-encoded protease cleaves the Gag polyprotein during or soon after assembly to allow the transformation from immature to mature particles (1). This process, termed maturation, is required for the production of infectious virions. Although Gag polyproteins from different retroviruses might have only limited sequence homology, they share three similarly organized, conserved domains: matrix (MA), capsid (CA), and nucleocapsid (NC). Additionally, Gag from different retroviruses can have other domains. For example, the proteolytic cleavage of HIV-1 Gag also yields spacer peptide 1 (SP1 or p2), SP2 (p1), and p6 proteins. In the immature particles, Gag forms an approximately spherical shell underlying the membrane (51). After cleavage from the polyprotein, the HIV-1 CA (hCA) protein undergoes structural refolding and reassembles into a cone-shaped core that encloses the genomic RNA, NC, reverse transcriptase, integrase, and other viral and host components (1, 6, 8). It has been estimated that, although each immature HIV-1 particle contains around 5,000 Gag proteins, the mature shell of HIV-1 contains 1,000 to 1,500 CA proteins assembled into a mostly hexameric lattice (7). Therefore, only a fraction of CA proteins generated from Gag cleavage are used to form one mature virion core.

We previously demonstrated that Gag proteins from HIV-1 and HIV-2 can coassemble and complement each other's functions (5). Because only a fraction of the mature CA proteins are used to generate a core, it is possible that only the CA proteins from one of the viruses are used to form a core. Coassembly of heterologous CA proteins into a core has not previously been demonstrated; therefore, it is unclear whether such a core can be formed and whether it is capable of conducting all steps leading to a successful infection. The mature CA proteins in the virion core play important roles in the viral replication cycle (14, 44, 45, 50, 52). After entry into the cells, virus uncoating occurs; CA proteins play an important role in regulating the uncoating process. Mutations in CA can lead to acceleration or delay of the uncoating events (14); both alterations can abolish the infectivity of HIV-1. Additionally, CA can influence the ability of HIV-1 to infect nondividing cells, possibly by affecting nuclear import (12, 53). Taken together, the identities of the CA proteins can affect the biological properties of the virus, and it is possible that a coassembled core can have properties different from those of the two parental viruses.

We sought to determine whether CA proteins from two different primate lentiviruses can coassemble into a mature core to carry out all the steps necessary for infection. We envisioned three possibilities for virions with heterologous Gag proteins: first, mature heterologous CA proteins do not coassemble and the cores consist of CA proteins from one virus (pure CA cores); second, heterologous CA proteins coassemble into a core (mixed CA core) but viruses containing mixed cores are not infectious; and third, heterologous CA proteins coassemble into a mixed core and viruses containing mixed cores are infectious. To answer our experimental question, we exploited the inhibitory specificity of the tripartite motif 5 protein from the rhesus monkey (rhTRIM5) for cores containing hCA but not SIV_mac CA (sCA).

TRIM5 is a member of the tripartite motif-containing family of proteins (35). The tripartite motif comprises a RING domain that includes two zinc finger motifs, one or two B-box domains, and a coiled-coil domain that mediates protein-protein interactions between TRIM family members (32, 41, 47). The rhTRIM5 protein restricts the replication of HIV-1 and HIV-2, but not SIV_mac, a virus closely related to HIV-2 (22, 41, 54, 55). Although the mechanism by which rhTRIM5 restricts HIV-1 replication is not fully elucidated, recent studies suggest that rhTRIM5 targets the incoming mature HIV-1 core to promote premature uncoating and possibly degradation of CA proteins (9, 42). However, the inhibition of HIV-1 infection imposed by TRIM5 can be saturated by overwhelming the system with restriction-sensitive mature viruses or virus-like particles (21, 39, 41, 54). Interestingly, TRIM5 restriction cannot be saturated by adding immature virions or particles with cores consisting of restriction-insensitive CA proteins (10, 13). Furthermore, saturation of TRIM5 restriction depends on the stability of the incoming HIV-1 capsid (39). These results strongly support the idea that TRIM5 recognizes CA that has undergone conformational changes or the tertiary structure of CA in the mature core.

N- and B-tropic murine leukemia viruses, two highly homologous virus strains that differ in their sensitivities to Fv-1 and TRIM5, were used to demonstrate that coassembled viruses were sensitive to host Fv-1 restriction (26, 34, 46). The restriction imposed by rhTRIM5 is specific to hCA and is relieved in HIV-1 particles that have cores containing sCA proteins (33). We hypothesize that, if hCA and sCA can coassemble into the same core, TRIM5 can recognize hCA present in the mixed CA core and restrict the infection of such viruses; in contrast, a population of pure CA core viruses, some with sCA cores and some with hCA cores, would generate a different restriction pattern. To determine whether hCA and sCA can coassemble to form a mixed core, we examined the TRIM5 restriction phenotypes of viruses containing two different types of Gag proteins, one with hCA and the other with sCA. To ensure that most of the infection events observed were from coassembled viruses, we used two modified viruses that each harbored a debilitating gag mutation so that viruses derived from neither mutant could replicate efficiently. However, Gag proteins from two mutants could coassemble to allow functional complementation, thereby rescuing efficient virus replication. Our results indicate that hCA and sCA can coassemble into a mixed CA core to produce infectious virus.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Plasmid construction. Plasmids were constructed with standard molecular cloning procedures (38). The general structures of all constructs were verified by restriction mapping, and PCR-amplified regions were further characterized by DNA sequencing to avoid inadvertent mutations. For clarity, pHDV-eGFP (48) and its derivative pHIV-Thy1 (36) are referred to as hCA-gfp and hCA-thy, respectively. For clarity, HIV-1-based vectors 1-NC-thy and 1-PTAP-gfp (5), containing mutations in the NC and PTAP regions of HIV-1 Gag, respectively, are referred to as hCA-NC*-thy and hCA-PTAP*-gfp, respectively. By overlapping PCR and cloning, most of the CA region (amino acids [aa] 1 to 204) in hCA-NC*-thy and hCA-PTAP*-gfp was replaced with sCA (aa 1 to 202) to generate sCA-NC*-thy and sCA-PTAP*-gfp, respectively. Vectors sCA-thy and sCA-gfp were constructed by replacing the AtaII-SbfI fragments in hCA-thy and hCA-gfp, respectively, with the corresponding fragment in NL43-sCA; NL43-sCA contains sCA (aa 1 to 202) in place of hCA (aa 1 to 204).

Cells, transfections, and infections. Cell line 293T and 293T cells expressing TRIM5 or empty plasmid have been previously described (41). These cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum, penicillin (50 U/ml), and streptomycin (50 U/ml). All cultured cells were maintained at 37°C with 5% CO₂.

To generate vector-derived viruses, 293T cells were transiently transfected with an HIV-1 vector and pHCMV-G, which expresses vesicular stomatitis virus G protein, using the MBS mammalian transfection kit (Stratagene). Viral supernatants were harvested 24 h later, clarified through a 0.45-µm-pore-size filter to remove cellular debris, and used immediately or stored at –80°C prior to infection.

For infection of 293T cells expressing TRIM5 or empty plasmid, 50,000 cells were plated in each well of a 24-well plate and infected 24 h later. Serial dilutions were generated from each viral stock and used to infect target cells in the presence of Polybrene at a final concentration of 10 µg/ml. Viruses were removed 2 h later, and fresh medium was added to the cells; target cells were processed 48 h postinfection, followed by flow cytometry analyses.

Antibody staining and flow cytometry analyses. Cells were stained with allophycocyanin-conjugated anti-Thy-1 antibody (eBioscience) and fixed with 2% paraformaldehyde prior to flow cytometry analyses. These assays were performed on a FACSCalibur apparatus (BD Biosciences), and data obtained were analyzed with Flowjo software (Tree Star). Infected cells were scored by expression of Thy or a green fluorescent protein (GFP) marker. Multiplicity of infection (MOI) was calculated from the number of infected cells obtained from flow cytometry as previously described (11).

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Strategy to examine whether CA proteins from distinct primate lentiviruses can coassemble to form infectious cores. To determine whether CA proteins from two different viruses can coassemble into mature cores to form infectious particles, we exploited the specificity of rhTRIM5 to restrict the replication of viruses containing the hCA core but not the sCA core. We previously observed that HIV-1 and HIV-2 Gag proteins can coassemble. Therefore, we expected that HIV-1 Gag molecules containing hCA can coassemble with those containing sCA (Fig. 1) because of the high similarity between SIV_mac and HIV-2 (83% amino acid sequence identity in Gag). Coassembled viruses that contain both types of Gag proteins would have two different mature CA proteins, hCA and sCA, after proteolytic cleavage. If hCA and sCA cannot coassemble into the same core, the virus preparation would be a mixture of particles with pure CA cores. Viruses with hCA cores would be restricted by rhTRIM5, whereas those with sCA would not. Therefore, the titer of such a virus preparation would be slightly decreased by rhTRIM5. In contrast, if hCA and sCA can coassemble to form a mixed CA core, rhTRIM5 would recognize and significantly restrict the infection of particles containing these cores. By determining the phenotypes of the coassembled viruses, we could determine whether hCA and sCA are coassembled in the cores of infectious particles.

View larger version (16K): [in this window] [in a new window]

FIG. 1. Strategy to examine whether hCA and sCA can coassemble into infectious mature cores. HIV-1 vectors encoding hCA or sCA and containing either a debilitating NC or PTAP mutation were cotransfected into 293T cells. Coassembly and functional complementation of the two mutant Gag proteins result in the production of infectious virus particles. After proteolytic cleavage during virus maturation, the coassembled viruses contain both mature hCA and sCA. It is possible that hCA and sCA cannot coassemble into the same core to generate infectious viruses, in which case the infectious virus population is a mixture of particles with pure cores consisting of either hCA or sCA. It is also possible that hCA and sCA can coassemble into the same core and that viruses containing these cores are infectious. To distinguish between these two possibilities, the virus preparation was used to infect 293T cells expressing rhTRIM5 or control 293T cells expressing the empty plasmid and the levels of infection were compared to determine the effect of rhTRIM5 restriction on virus infectivities.

Characterization and complementation of the mutant constructs. To ensure that most of the infectious viruses contained both Gag proteins, we introduced mutations in either the NC domains or the PTAP motifs of our vectors. The NC mutation replaces the conserved CCHC/CCHC with CCHH/CCCC and drastically decreases the viral RNA encapsidation and virus titer (18). The PTAP mutation changes PTAP to LIRL and significantly reduces the virus production and virus titer (23). When coexpressed in the HIV-1 context, these two mutants can complement each other to generate infectious viruses with mostly restored infectivity (5).

To implement this strategy, we used several HIV-1-based vectors that contain cis-acting elements essential for viral replication and express gag-pol, tat, rev, and a marker gene, either thy or gfp (Fig. 2). The vector name indicates the identity of the CA, nature of the mutation, and encoded marker. For example, hCA-thy expresses wild-type HIV-1 gag-pol, sCA-thy expresses a functional chimeric gag-pol with most of the CA-encoding domain derived from SIV_mac, and hCA-NC*-thy expresses HIV-1 gag-pol encoding a mutation in NC; additionally, these three vectors express the thy marker.

View larger version (26K): [in this window] [in a new window]

FIG. 2. General structure of HIV-1-based vectors. These vectors express gag-pol, tat, rev, and a marker gene, either gfp or thy. The Gag domains MA, CA, NC, and p6 are indicated. The asterisks indicate the locations of the mutations. LTR, long terminal repeat.

To measure the viral titer generated by each vector, we transfected the vector plasmid into 293T cells along with pHCMV-G, which expresses vesicular stomatitis virus G protein. Viruses were harvested from transfected cells and used to infect fresh 293T cells; infected cells were later analyzed by flow cytometry. Representative flow cytometry analyses are shown in the top and middle panels of Fig. 3. As expected, the NC mutants and PTAP mutants generated drastically decreased titers compared with titers generated by hCA vectors and sCA vectors that contain functional gag-pol.

View larger version (44K): [in this window] [in a new window]

FIG. 3. Representative flow cytometry analyses of infection by various viruses. The axes indicate Thy expression and GFP expression. (Top) Infection by viruses generated by wild-type or mutant vectors containing hCA. (Middle) Infection by viruses generated by wild-type or mutant vectors containing sCA. (Bottom) Infection by viruses generated from cotransfection of vectors containing an NC or PTAP mutation.

To ensure that Gag-containing hCA and sCA can coassemble and complement each other's function, we cotransfected two constructs, one with an NC mutation and one with a PTAP mutation, and examined the viral titers generated from these transfections. As shown in the bottom panels of Fig. 3, two hCA-containing or two sCA-containing Gag proteins can complement each other's function. Furthermore, hCA-containing and sCA-containing Gag proteins can also complement each other's function to generate robust viral titers. The successful complementation between vectors with heterologous CA domains provided the opportunity to study whether heterologous CA proteins coassemble into infectious viral cores.

TRIM5 restriction in viruses with pure CA cores consisting of either hCA or sCA. Several reports have demonstrated that TRIM5 restriction can be saturated and that the level of restriction depends on the amount of virus used for infection (4, 10, 13, 21, 39, 41, 54). To examine TRIM5 restriction of virus infection, we serially diluted each viral preparation and measured viral titers generated from infecting 293T cells expressing rhTRIM5 and control 293T cells expressing an empty vector; for simplicity, these cells will be referred to as TRIM5 cells and control cells, respectively. We then converted the percentage of infection to MOI and calculated the level of restriction by dividing the MOI in control cells by the MOI in TRIM5 cells at a given dilution of a viral stock. Three independent experiments were performed and generated similar results; representative results of restriction in viruses derived from hCA-gfp or sCA-thy are shown in Fig. 4A and Table 1. Viruses generated from hCA-gfp alone (Fig. 4A) were greatly restricted in TRIM5 cells compared with those in control cells; consistent with the previous observations, the levels of restriction were affected by the amount of the input virus. Using serially diluted hCA-gfp viruses, we determined that the percentages of infection for TRIM5 cells compared with those for control cells were 24% versus 95.3%, 4% versus 73.2%, and 1.3% versus 46.3%, which resulted in an 11- to 48-fold restriction. In contrast, sCA-thy-derived viruses (Fig. 4A) generated similar percentages of infection in TRIM5 and control cells: 72.2% versus 73.8%, 52.5% versus 56.50%, 40.50% versus 40.90%, 24.8% versus 28.6%, and 11.4% versus 14% (Fig. 4A and Table 1).

View larger version (24K): [in this window] [in a new window]

FIG. 4. Restriction patterns of viruses. (A) Representative results of TRIM5 restriction for viruses containing pure cores. Separately produced viruses were mixed at various ratios, and the restriction levels of such virus mixtures were determined. Three sets of independent experiments were performed and yielded similar results; in all experiments, the mixed viruses never achieved more than threefold restriction. (B) Representative results of TRIM5 restriction in viruses produced by cotransfection of NC or PTAP mutants with homologous or heterologous CA proteins. All three independent experiments generated similar results. In each experiment, viruses containing only hCA had the highest restriction, whereas viruses containing only sCA did not have significant restriction. Among the mixed viruses, restriction decreased with smaller amounts of hCA. In the three sets of experiments, when the control cells were infected at 50% and hCA- and sCA-encoding plasmids were transfected at 1:1, 1:2, and 1:4 ratios, we estimated that TRIM5 restricted the virus titers 11- to 13-fold, 7- to 9-fold, and 5- to 8-fold, respectively. Restriction values were calculated by dividing the MOI in control cells by the MOI in rhTRIM5 cells.

View this table: [in this window] [in a new window]

TABLE 1. TRIM5 restriction of a mixture of separately produced viruses

We then tested the effect of infecting cells with a mixture of viruses, some containing hCA cores and the others sCA cores. Virus stocks were generated separately, derived either from hCA-gfp or from sCA-thy; these two virus stocks were then added together at various ratios and used to infect TRIM5 and control cells; the infected cells in both cell lines were measured, and levels of TRIM5 restriction were determined. When viral stocks of hCA-gfp and sCA-thy were mixed at equal amounts, a 2- to 2.5-fold restriction was observed, whereas when viral stocks of hCA-gfp and sCA-thy were mixed at 1:2 and 1:4 ratios, very little restriction was observed in both mixtures. We reasoned that the virus population with sCA would infect both TRIM5 cells and control cells equally well, whereas the virus population with hCA cores would infect TRIM5 cells poorly compared with control cells. When the effects of the two populations were added together, we should observe a very mild restriction. A theoretical simulation of this scenario is shown in Table 2. For example, if we have a mixture of viruses and half of the viruses contain hCA cores and half contain sCA cores, each infecting 5% of control cells, then infection of 10% of the control cells should be detected. If hCA virus is restricted by 50-fold in the TRIM5 cells, it would yield 0.2% infection. Because sCA virus is not restricted by rhTRIM5, it would yield 5% infection; together, these infection levels imply that a total of 5.2% of the TRIM5 cells should be infected. The level of restriction is calculated by comparing the control cell infection (10%) with the TRIM5 cell infection (5.2%), which yields approximately twofold restriction. The level of restriction would decrease when the relative amounts of sCA virus increase (Table 2). These predictions are consistent with our results for virus populations containing pure CA cores.

View this table: [in this window] [in a new window]

TABLE 2. Simulation of restriction in mixed viral populations containing pure cores

TRIM5 restriction phenotypes of viruses containing both hCA and sCA proteins. To determine whether heterologous CA proteins can coassemble into cores of infectious viruses, we examined the restriction phenotypes of viruses generated by cotransfected vectors hCA-NC*-thy and sCA-PTAP*-gfp. A total of three independent experiments were performed, which yielded similar results; data from one set of representative experiments are shown in Table 3 and Fig. 4B. For controls, we also examined the restriction phenotypes of viruses generated from cotransfecting at a 1:1 ratio either two hCA-containing vectors (hCA-NC*-thy and sCA-PTAP*-gfp) or two sCA-containing vectors (sCA-NC*-thy and sCA-PTAP*-gfp). As expected, we observed strong rhTRIM5 restriction when both vectors used in the complementation system contained hCA and little, if any, restriction when both vectors contained sCA (Fig. 4B).

View this table: [in this window] [in a new window]

TABLE 3. TRIM5 restriction of viruses generated from cotransfection of two vectors

The phenotypes of viruses containing both hCA and sCA proteins are also shown in Fig. 4B. We observed significant restriction in viruses generated by cotransfecting hCA-NC*-thy and sCA-PTAP*-gfp. However, the levels of restriction are lower than those in viruses containing only hCA proteins (Fig. 4B). When hCA- and sCA-expressing vectors were mixed at equal amounts, the resulting viruses were restricted 3.6- to 17.3-fold by rhTRIM5 cells, depending on the titer of infection (Fig. 4B). Even when hCA-expressing vectors were present at 20% of the mixture, the resulting viruses were restricted 4.4- to 10.5-fold by rhTRIM5 cells depending on the titer of infection (Fig. 4B). These results are in sharp contrast to those shown in Fig. 4A, when pure CA core viruses from separate transfection were mixed prior to infection. First, these coassembled Gag viruses had far greater levels of restriction than the pure CA core viruses in Fig. 4A, which had a maximum of only 2- to 2.5-fold restriction in the 1:1 (hCA-sCA) mixture. Additionally, the levels of restriction of coassembled Gag viruses are heavily influenced by the amounts of input viruses, similar to the restriction kinetics of HIV-1, and are very different from those of pure CA core viruses (Fig. 4A). These results support the conclusion that hCA and sCA can coassemble into the same mature cores and that such cores are susceptible to rhTRIM5 restriction. Furthermore, cores containing coassembled hCA and sCA are capable of completing steps of HIV-1 replication to lead to successful infection.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
In this study, we exploited the specificity of rhTRIM5 for hCA in the mature viral core to demonstrate that CA proteins from HIV-1 and SIV_mac can coassemble into the same core to generate infectious viruses. To our knowledge, this is the first demonstration that CA proteins from distinct retroviruses can coassemble into an infectious mature core.

Primate lentiviruses consist of HIV-1, HIV-2, and various simian immunodeficiency virus strains isolated from more than 30 nonhuman primate species; most of these viruses can be assigned to one of the six approximately equidistant phylogenetic lineages (37). Generally, the Gag proteins from viruses of different phylogenetic lineages are around 50% identical in amino acid sequences, whereas the Gag proteins from viruses of the same phylogenetic lineage are usually more than 80% identical in amino acid sequences (HIV databases, http://www.hiv.lanl.gov). HIV-2 and SIV_mac belong to the same phylogenetic lineage, whereas HIV-1 belongs to a different lineage. In terms of amino acid sequence, the Gag proteins of HIV-2 and SIV_mac share 83% identity, whereas these two proteins share 54% and 53% identity with HIV-1 Gag, respectively. Among the Gag domains of primate lentiviruses, CA domains usually have the highest similarity. The CA proteins of HIV-2 and SIV_mac share 90% amino acid identity, whereas these two proteins share 68% and 66% identity with HIV-1 CA protein. The overall higher conservation of the CA domain relative to other domains is probably due to the evolutionary constraints imposed by the multiple roles that CA plays during retrovirus replication, both as a Gag domain and as a mature protein.

Our current understanding of virus maturation is that core formation is not simply condensation of the CA domain of the Gag lattice after proteolytic cleavage. Rather, a second assembly step, including the refolding of the mature CA protein and formation of a hexamer CA lattice, is involved in the formation of the cone-shaped core (49). The structure and protein-protein interactions of mature retrovirus cores are just beginning to be elucidated. The core of HIV-1 is proposed to be a fullerene structure composed of 200 to 300 CA hexamers and 12 CA pentamers (17, 30). Recent structural analyses revealed that there are three important protein-protein interaction interfaces in the mature core (16, 28, 29). Helices 1 to 3 in the N-terminal domain of CA mediate the N-terminal-N-terminal hexamerization interaction interface. Helix 9 in the C-terminal domain primarily mediates the C-terminal-C-terminal dimerization interaction. Helix 4 in the N-terminal domain and helices 8 to 11 in the C-terminal domain are involved in the N-terminal-C-terminal interaction. Therefore, extensive interactions between neighboring CA molecules in the hexameric lattice are required in forming a mature core. Although our current knowledge does not extend to the detailed CA-CA side chain interactions in immature or mature particles, mutagenesis analyses have identified a number of amino acids potentially involved in these interactions. Mutations R18A/N21A, A22D, E28A/E29A, M39D, A42D, D51A, T54A/N57A, and K70A have been shown to reduce or alter mature core formation, whereas mutations E75A/E76A, R100A/S102A, T107A/T108A, T110A/Q112A, K158ADQ, W184A, M18A, and D197AEN diminish immature particle production (50). Most of these amino acids are conserved between hCA and sCA. However, M39, T54, K70, R100, T110, and Q112 in hCA are changed to G, Q, R, S, S, and D in sCA, respectively. These differences appear to be tolerated and do not prevent the coassembly of Gag proteins containing CA domains from HIV-1 and SIV_mac or the formation of mature cores from these heterologous CA proteins. What remains unknown is the arrangement of these heterologous CA proteins in the mature core. For example, it is not clear whether these two different CA proteins are evenly distributed in the core and whether these two different CA proteins form mixed hexamers.

We demonstrated that viruses containing hCA and sCA were restricted by rhTRIM5 in a virus titer-dependent manner. However, the level of rhTRIM5 restriction in these viruses was less than that in viruses containing pure hCA cores at a comparable infection rate (Fig. 4B). Furthermore, the levels of restriction are directly correlated with the amount of hCA-containing vector used in transfection. For example, when control cells were infected at about the 55% level, the restriction in hCA cores is about 27-fold (Fig. 4B and Table 3); when the hCA and sCA ratios are 1:1, and 1:2, the restriction levels are about 11-fold and 8-fold, respectively; and when the hCA and sCA ratio is 1:4, the restriction is estimated to be 6-fold. Therefore, these mixed-core viruses have an intermediate phenotype and the restriction levels are in proportion to the amounts of hCA in the mixture. These results reveal that the number of TRIM5 binding sites in the cores is an important limiting factor of restriction. It is possible that multiple TRIM5 binding is required to achieve restriction or that TRIM5 finding the target hCA is a rate-limiting step. Therefore, decreasing the number of target hCA proteins causes the reduction of TRIM5 restriction efficiency. Experimental evidence indicates that TRIM5 is a trimer, and it has been proposed that the three molecules of the trimer can fit into three binding pockets in a CA hexamer or between hexamers (24, 31). If each of the molecules in the trimer needs to bind a pocket to be functional and hCA and sCA assemble randomly, then the probability of a TRIM5 trimer finding all three binding pockets to be suitable should be reduced nonlinearly with the decrease in the amounts of hCA. For example, when hCA and sCA are mixed in 1:1, 1:2, and 1:4 ratios, the probability of a trimer finding three suitable binding sites should be 1 in 8 (2³), 1 in 27 (3³), and 1 in 125 (5³), respectively. These probabilities are reduced even more drastically if more than one hCA protein is required to form each binding pocket. In either scenario, the numbers of sites for binding to TRIM5 trimers in the core are not linear to the amounts of hCA proteins in the core. Our data indicate a nearly linear relationship between the proportion of hCA in the virus and the restriction level, thereby suggesting either that all three TRIM5 molecules in the trimer are not required to bind to the core to be functional or that hCA and sCA are not distributed randomly in the core because homologous CA proteins have stronger affinity to each other than to heterologous CA proteins. To distinguish between these two possibilities requires further advances in our understanding of TRIM5-CA binding and the assembly of heterologous CA proteins in virus cores.

In this report, we illustrate that sufficient features are conserved between CA proteins from HIV-1 and SIV_mac to allow coassembly of infectious virus cores. The mixed cores have an intermediate phenotype in terms of restriction by TRIM5. One possible implication is that virus could use this mechanism to lower the efficiency of the host innate defense system to initiate infection. These experiments are the first to demonstrate that heterologous CA proteins can coassemble into mature cores of infectious viruses and have implications for virus evolution. These studies also provide insights into the mechanisms of TRIM5 restriction and virus assembly.

 
We thank Anne Arthur for her expert editorial help, Matthew Stremlau and Joseph Sodroski for the generous gifts of TRIM5 and control cell lines, and Eric Freed and Alan Rein for their input and critical reading of the manuscript.

This research was supported by the Intramural Research Program of the NIH, including an IATAP grant, and the Center for Cancer Research, National Cancer Institute.

 
* Corresponding author. Mailing address: HIV Drug Resistance Program, NCI-Frederick, P.O. Box B, Building 535, Room 336, Frederick, MD 21702. Phone: (301) 846-1250. Fax: (301) 846-6013. E-mail: whu{at}ncifcrf.gov

Published ahead of print on 25 June 2008.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1
1. Adamson, C. S., and E. O. Freed. 2007. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv. Pharmacol. 55:347-387.[CrossRef][Medline]
2
2. Arien, K. K., A. Abraha, M. E. Quinones-Mateu, L. Kestens, G. Vanham, and E. J. Arts. 2005. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79:8979-8990.[Abstract/Free Full Text]
3
3. Bailes, E., F. Gao, F. Bibollet-Ruche, V. Courgnaud, M. Peeters, P. A. Marx, B. H. Hahn, and P. M. Sharp. 2003. Hybrid origin of SIV in chimpanzees. Science 300:1713.[Free Full Text]
4
4. Besnier, C., Y. Takeuchi, and G. Towers. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. USA 99:11920-11925.[Abstract/Free Full Text]
5
5. Boyko, V., M. Leavitt, R. Gorelick, W. Fu, O. Nikolaitchik, V. K. Pathak, K. Nagashima, and W.-S. Hu. 2006. Coassembly and complementation of Gag proteins from HIV-1 and HIV-2, two distinct human pathogens. Mol. Cell 23:281.[CrossRef][Medline]
6
6. Briggs, J. A. G., K. Grunewald, B. Glass, F. Forster, H.-G. Krausslich, and S. D. Fuller. 2006. The mechanism of HIV-1 core assembly: insights from three dimensional reconstructions of authentic virions. Structure 14:15-20.[Medline]
7
7. Briggs, J. A. G., M. N. Simon, I. Gross, H.-G. Krausslich, S. D. Fuller, V. M. Vogt, and M. C. Johnson. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675.[CrossRef][Medline]
8
8. Briggs, J. A. G., T. Wilk, R. Welker, H.-G. Krausslich, and S. D. Fuller. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22:1707-1716.[CrossRef][Medline]
9
9. Chatterji, U., M. D. Bobardt, P. Gaskill, D. Sheeter, H. Fox, and P. A. Gallay. 2006. Trim5 accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J. Biol. Chem. 281:37025-37033.[Abstract/Free Full Text]
10
10. Cowan, S., T. Hatziioannou, T. Cunningham, M. A. Muesing, H. G. Gottlinger, and P. D. Bieniasz. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA 99:11914-11919.[Abstract/Free Full Text]
11
11. Dang, Q., J. Chen, D. Unutmaz, J. M. Coffin, V. K. Pathak, D. Powell, V. N. KewalRamani, F. Maldarelli, and W. S. Hu. 2004. Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc. Natl. Acad. Sci. USA 101:632-637.[Abstract/Free Full Text]
12
12. Dismuke, D. J., and C. Aiken. 2006. Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J. Virol. 80:3712-3720.[Abstract/Free Full Text]
13
13. Dodding, M. P., M. Bock, M. W. Yap, and J. P. Stoye. 2005. Capsid processing requirements for abrogation of Fv1 and Ref1 restriction. J. Virol. 79:10571-10577.[Abstract/Free Full Text]
14
14. Forshey, B. M., U. von Schwedler, W. I. Sundquist, and C. Aiken. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.[Abstract/Free Full Text]
15
15. Freed, E. O. 2002. Viral late domains. J. Virol. 76:4679-4687.[Free Full Text]
16
16. Ganser-Pornillos, B. K., A. Cheng, and M. Yeager. 2007. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131:70-79.[CrossRef][Medline]
17
17. Ganser-Pornillos, B. K., S. Li, V. Klishko, J. T. Finch, and W. I. Sundquist. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83.[Abstract/Free Full Text]
18
18. Gorelick, R. J., T. D. Gagliardi, W. J. Bosche, T. A. Wiltrout, L. V. Coren, D. J. Chabot, J. D. Lifson, L. E. Henderson, and L. O. Arthur. 1999. Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences. Virology 256:92.[CrossRef][Medline]
19
19. Gottlieb, G. S., P. S. Sow, S. E. Hawes, I. Ndoye, A. M. Coll-Seck, M. E. Curlin, C. W. Critchlow, N. B. Kiviat, and J. I. Mullins. 2003. Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. AIDS Res. Hum. Retrovir. 19:575-584.[CrossRef][Medline]
20
20. Gottlinger, H. G. 2001. The HIV-1 assembly machine. AIDS 15:S13-S20.[CrossRef]
21
21. Hatziioannou, T., S. Cowan, S. P. Goff, P. D. Bieniasz, and G. J. Towers. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-394.[CrossRef][Medline]
22
22. Hatziioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5. Proc. Natl. Acad. Sci. USA 101:10774-10779.[Abstract/Free Full Text]
23
23. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-6818.[Abstract]
24
24. Javanbakht, H., W. Yuan, D. F. Yeung, B. Song, F. Diaz-Griffero, Y. Li, X. Li, M. Stremlau, and J. Sodroski. 2006. Characterization of TRIM5 trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353:234-246.[CrossRef][Medline]
25
25. Kannangai, R., R. V. Shaji, S. Ramalingam, M. V. Jesudason, O. C. Abraham, R. George, A. P. Shanmugam, D. H. Schwartz, and G. Sridharan. 2003. HIV-2 subtype circulating in India (south). J. Acquir. Immune Defic. Syndr. 33:219-222.[CrossRef][Medline]
26
26. Kashmiri, S. V., A. Rein, R. H. Bassin, B. I. Gerwin, and S. Gisselbrecht. 1977. Donation of N- or B-tropic phenotype to NB-tropic murine leukemia virus during mixed infections. J. Virol. 22:626-633.[Abstract/Free Full Text]
27
27. Landau, N. R., K. A. Page, and D. R. Littman. 1991. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J. Virol. 65:162-169.[Abstract/Free Full Text]
28
28. Lanman, J., T. T. Lam, S. Barnes, M. Sakalian, M. R. Emmett, A. G. Marshall, and P. E. Prevelige. 2003. Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry. J. Mol. Biol. 325:759-772.[CrossRef][Medline]
29
29. Lanman, J., T. T. Lam, M. R. Emmett, A. G. Marshall, M. Sakalian, and P. E. Prevelige, Jr. 2004. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nat. Struct. Mol. Biol. 11:676-677.[CrossRef][Medline]
30
30. Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch. 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409-413.[CrossRef][Medline]
31
31. Mische, C. C., H. Javanbakht, B. Song, F. Diaz-Griffero, M. Stremlau, B. Strack, Z. Si, and J. Sodroski. 2005. Retroviral restriction factor TRIM5 is a trimer. J. Virol. 79:14446-14450.[Abstract/Free Full Text]
32
32. Nisole, S., J. P. Stoye, and A. Saib. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 3:799-808.[CrossRef][Medline]
33
33. Owens, C. M., P. C. Yang, H. Gottlinger, and J. Sodroski. 2003. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J. Virol. 77:726-731.[CrossRef][Medline]
34
34. Rein, A., S. V. Kashmiri, R. H. Bassin, B. L. Gerwin, and G. Duran-Troise. 1976. Phenotypic mixing between N- and B-tropic murine leukemia viruses: infectious particles with dual sensitivity to Fv-1 restriction. Cell 7:373-379.[CrossRef][Medline]
35
35. Reymond, A., G. Meroni, A. Fantozzi, G. Meria, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballobio. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.[CrossRef][Medline]
36
36. Rhodes, T., O. Nikolaitchik, J. Chen, D. Powell, and W. S. Hu. 2005. Genetic recombination of human immunodeficiency virus type I in one round of viral replication: effects of genetic distance, target cells, accessory genes, and lack of high negative interference in crossover events. J. Virol. 79:1666-1677.[Abstract/Free Full Text]
37
37. Salemi, M., T. De Oliveira, V. Courgnaud, V. Moulton, B. Holland, S. Cassol, W. M. Switzer, and A.-M. Vandamme. 2003. Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. J. Virol. 77:7202-7213.[Abstract/Free Full Text]
38
38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
39
39. Shi, J., and C. Aiken. 2006. Saturation of TRIM5-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 350:493-500.[CrossRef][Medline]
40
40. Spector, D. H., E. Wade, D. A. Wright, V. Koval, C. Clark, D. Jaquish, and S. A. Spector. 1990. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J. Virol. 64:2298-2308.[Abstract/Free Full Text]
41
41. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5 restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.[CrossRef][Medline]
42
42. Stremlau, M., M. Perron, M. Lee, Y. Li, B. Song, H. Javanbakht, F. Diaz-Griffero, D. J. Anderson, W. I. Sundquist, and J. Sodroski. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 restriction factor. Proc. Natl. Acad. Sci. USA 103:5514-5519.[Abstract/Free Full Text]
43
43. Swanstrom, R., and J. W. S. Wills. 1997. Synthesis, assembly, and processing of viral proteins. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
44
44. Tang, S., T. Murakami, B. E. Agresta, S. Campbell, E. O. Freed, and J. G. Levin. 2001. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J. Virol. 75:9357-9366.[Abstract/Free Full Text]
45
45. Tang, S., T. Murakami, N. Cheng, A. C. Steven, E. O. Freed, and J. G. Levin. 2003. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J. Virol. 77:12592-12602.[Abstract/Free Full Text]
46
46. Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos. 2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA 97:12295-12299.[Abstract/Free Full Text]
47
47. Towers, G. J. 2007. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4:40-49.[CrossRef][Medline]
48
48. Unutmaz, D., V. N. KewalRamani, S. Marmon, and D. R. Littman. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746.[Abstract/Free Full Text]
49
49. von Schwedler, U., T. Stemmler, V. Klishko, S. Li, K. Albertine, D. Davis, and W. I. Sundquist. 1998. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17:1555-1568.[CrossRef][Medline]
50
50. von Schwedler, U. K., K. M. Stray, J. E. Garrus, and W. I. Sundquist. 2003. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77:5439-5450.[Abstract/Free Full Text]
51
51. Wilk, T., I. Gross, B. E. Gowen, T. Rutten, F. de Haas, R. Welker, H.-G. Krausslich, P. Boulanger, and S. D. Fuller. 2001. Organization of immature human immunodeficiency virus type 1. J. Virol. 75:759-771.[Abstract/Free Full Text]
52
52. Yamashita, M., and M. Emerman. 2004. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78:5670-5678.[Abstract/Free Full Text]
53
53. Yamashita, M., O. Perez, T. J. Hope, and M. Emerman. 2007. Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog. 3:1502-1510.[Medline]
54
54. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5 protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.[Abstract/Free Full Text]
55
55. Ylinen, L. M. J., Z. Keckesova, S. J. Wilson, S. Ranasinghe, and G. J. Towers. 2005. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5 alleles. J. Virol. 79:11580-11587.[Abstract/Free Full Text]

---

Journal of Virology, September 2008, p. 8253-8261, Vol. 82, No. 17
0022-538X/08/$08.00+0     doi:10.1128/JVI.02663-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Hu, W.-S. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Hu, W.-S.